Sensome

Executive Summary

Sensome is a French medical device company developing a breakthrough microchip-based tissue-sensing technology designed to be embedded into minimally invasive instruments. The technology uses bioimpedance to provide real-time, patient-specific information during procedures, enabling physicians to make faster and more effective treatment decisions. Initially targeting cardiovascular applications, Sensome's smart connected devices aim to transform interventional medicine by offering real-time tissue characterization without the need for additional imaging. Founded in 2015, the company is currently in Phase 1 development, focusing on technical validation and early clinical feasibility. With a strong intellectual property portfolio and proprietary integration processes, Sensome is well-positioned to partner with leading device manufacturers to bring its technology to market. The company's approach addresses a critical need for real-time tissue feedback during minimally invasive procedures, potentially improving outcomes and reducing procedure times.

Upcoming Catalysts (preview)

• Q1 2027First-in-human study results demonstrating safety and feasibility of sensor-equipped catheter40% success
• Q4 2026Partnership with major cardiovascular device manufacturer for co-development35% success
• Q3 2027CE marking submission for initial product in Europe25% success